- Home
- TCRX vs KUKE Comparison
TCRX vs KUKE Comparison
Compare TCRX & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- KUKE
- Stock Information
- Founded
- TCRX 2018
- KUKE 2002
- Country
- TCRX United States
- KUKE China
- Employees
- TCRX N/A
- KUKE N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- KUKE Other Consumer Services
- Sector
- TCRX Health Care
- KUKE Real Estate
- Exchange
- TCRX Nasdaq
- KUKE Nasdaq
- Market Cap
- TCRX 98.5M
- KUKE 91.9M
- IPO Year
- TCRX 2021
- KUKE 2021
- Fundamental
- Price
- TCRX $1.38
- KUKE $2.89
- Analyst Decision
- TCRX Strong Buy
- KUKE
- Analyst Count
- TCRX 6
- KUKE 0
- Target Price
- TCRX $9.83
- KUKE N/A
- AVG Volume (30 Days)
- TCRX 442.7K
- KUKE 229.4K
- Earning Date
- TCRX 03-05-2025
- KUKE 04-15-2025
- Dividend Yield
- TCRX N/A
- KUKE N/A
- EPS Growth
- TCRX N/A
- KUKE N/A
- EPS
- TCRX N/A
- KUKE N/A
- Revenue
- TCRX $2,816,000.00
- KUKE $14,784,158.00
- Revenue This Year
- TCRX $32.21
- KUKE N/A
- Revenue Next Year
- TCRX $118.35
- KUKE N/A
- P/E Ratio
- TCRX N/A
- KUKE N/A
- Revenue Growth
- TCRX N/A
- KUKE 10.48
- 52 Week Low
- TCRX $1.28
- KUKE $0.15
- 52 Week High
- TCRX $9.69
- KUKE $4.07
- Technical
- Relative Strength Index (RSI)
- TCRX 31.10
- KUKE 69.21
- Support Level
- TCRX $1.44
- KUKE $2.61
- Resistance Level
- TCRX $1.76
- KUKE $3.14
- Average True Range (ATR)
- TCRX 0.17
- KUKE 0.51
- MACD
- TCRX -0.01
- KUKE 0.09
- Stochastic Oscillator
- TCRX 16.39
- KUKE 85.14
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About KUKE Kuke Music Holding Limited
Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.